HMHA1
Reactivity: Human, Rat, Mouse, Cow, Dog, Pig, Hamster, Monkey, Bat, Chicken
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
WB: 1:500-1:2000, IHC: 1:20-1:200
Restrictions
For Research Use only
Format
Liquid
Buffer
PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
-20°C for 12 months (Avoid repeated freeze / thaw cycles.)
Expiry Date
12 months
Target
HMHA1
(Histocompatibility (Minor) HA-1 (HMHA1))
Alternative Name
HMHA1
Background
Synonyms:KIAA0223 Background:GTPase activator for the Rho-type GTPases. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens(mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease(GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation(BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte(CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.